QTc interval prolongation for patients in methadone maintenance treatment: A five years follow-up study

American Journal of Drug and Alcohol Abuse

Volumn 39, Issue 4, 2013, Pages 235-240

  Fareed, Ayman ^a,b   Vayalapalli, Sreedevi ^a,b   Scheinberg, Kelly ^a,b   Gale, Robin ^b   Casarella, Jennifer ^a,b   Drexler, Karen ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Methadone maintenance; Prolongation; QTc interval

Indexed keywords

COCAINE;

ADULT; ARTICLE; COCAINE DEPENDENCE; CONGESTIVE HEART FAILURE; DATA ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHADONE TREATMENT; PATIENT; QT PROLONGATION; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84880236894     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2013.804525     Document Type: Article

References (33)

1. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. JAMA 1965;193:80-84.
2. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 1966;66:2011-2017.
3. Krantz M, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-504. (Pubitemid 35024621)
4. Cruciani RA. Methadone: To ECG or not to ECG.That is still the question. J Pain Symptom Manage 2008;36:545-552. [Epub 2008 Apr 28].
5. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167:2469-2475. (Pubitemid 350254906)
6. Latowsky M. Methadone death, dosage, and torsade de pointes: Risk-benefit policy implications. J Psychoactive Drugs 2006;38: 513-519. (Pubitemid 46340096)
7. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506. (Pubitemid 37186911)
8. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005;11:44-49.[ PMID: 15608471]. (Pubitemid 40082210)
9. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007;93:1051-1055. [PMID: 17344330]. (Pubitemid 47310981)
10. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005;29:385-391. PMID: 15857742]. (Pubitemid 40602519)
11. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005;95:915-918. [PMID: 15781034]. (Pubitemid 40386816)
12. Committee for Proprietary Medicinal Products. Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products. vol. CPMP 986/96. London: The European Agency for the Evaluation of Medicinal Products; 1997.
13. U.S. Food and Drug Administration. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Rockville (MD): Center for Drug Evaluation and Research; 2005.
14. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with non antiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002;89:1316-1319. [PMID: 12031739]. (Pubitemid 34606900)
15. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MCP. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387-395.
16. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: A crosssectional study. Addiction 2007;102:289-300. [PMID: 17222284]. (Pubitemid 46096291)
17. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802-805. PMID: 12820821]. (Pubitemid 36629083)
18. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-504. (Pubitemid 35024621)
19. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, Piguet V, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: High frequency in hospitalized patients and risk factors. Arch Intern Med 2006;166:1280-1287. [PMID: 16801510]. (Pubitemid 43967579)
20. Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: Who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug Alcohol Rev 2011;30:388-396.
21. Krook AL, Waal H, Hansteen V. Routine ECG in methadoneassisted rehabilitation is wrong prioritization. [Norwegian]. Tidsskr Nor Laegeforen 2004;124:2940-2941.
22. MEDSAFE. Cardiac vigilance recommended for methadone: New Zealand medicines and medical devices safety authority. Prescriber Update 2, 23-25. 2005. Ref Type: Generic.
23. DH. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health; 2007.
24. Fareed A, Vayalapalli S, Byrd Sellers J, Casarella J, Drexler K, Amar J, Cox J, Shaw-Lutchman T. Onsite QTc interval screening for patients in methadone maintenance treatment. J Addict Dis 2010;29:15-22.
25. Huh B, Park CH. Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients. Korean J Anesthesiol 2010;58:338-343.
26. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN. Influence of opioid agonists on cardiac human ether-a-go-go- related gene K+ currents. J Pharmacol Exp Ther 2002;303:688-694. [PMID: 12388652]. (Pubitemid 35231242)
27. Ferreira S, Crumb WJ Jr, Carlton CG, Clarkson CW. Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. J Pharmacol Exp Ther 2001;299:220-226. [PMID: 11561083]. (Pubitemid 32905138)
28. Selby JV, FitzSimmons SC, Newman JM, Katz PP, Sepe S, Showstack J. The natural history and epidemiology of diabetic nephropathy: Implications for prevention and control. JAMA 1990; 263:1954-1960. (Pubitemid 20134773)
29. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetes Retinopathy III: Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Opthalmol 1984;102:527-532. (Pubitemid 14127839)
30. Laditka SB, Mastanduno P, Laditka JN. Health care use of individuals with diabetes in an employer-based insurance population. Arch Int Med 2001;161:1301-1308. (Pubitemid 32679580)
31. Kakko J, Grönbladh L, Svanborg KD, von Wachenfeldt J, Rück C, Rawlings B, Nilsson LH, Heilig M. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. Am J Psychiatry 2007;164:797-803. (Pubitemid 46808535)
32. Stallvik M, Nordstrand B, Kristensen O, Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine - relation to doses and serum concentrations. Drug Alcohol Depend 2013;129:88-93.
33. Fareed A, Byrd-Sellers J, Vayalapalli S, Drexler K, Phillips LS. Predictors of diabetes mellitus and abnormal blood glucose in patients receiving opioid maintenance treatment. Am J Addict (in press). DOI: 10.1111/j.1521-0391. 2013.12043.x.